Bicycle Therapeutics plc: Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Toxin Conjugates (BTCs) and tumor targeted immune cell agonists (TICAs)
Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones
First clinical trial site outside of the United States opened in ongoing Phase I/II trial of BT8009
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today reported financial results for the fourth quarter and full year ended December 31, 2020 and discussed recent corporate updates.